Predictors of tolerability for postoperative adjuvant S1 plus docetaxel chemotherapy for gastric cancer: a multicenter retrospective study

被引：0

作者：

Toyota, Kazuhiro ^{[1
]}

Tanabe, Kazuaki ^{[2
]}

Kano, Mikihiro ^{[3
]}

Komo, Toshiaki ^{[4
]}

Hotta, Ryuichi ^{[5
]}

Yanagawa, Senichiro ^{[6
]}

Saeki, Yoshihiro ^{[7
]}

Tazawa, Hirofumi ^{[8
]}

Ikeda, Masahiro ^{[9
]}

Shishida, Masayuki ^{[10
]}

Okano, Keisuke ^{[11
]}

Ide, Ryuta ^{[12
]}

Imaoka, Yasuhiro ^{[13
]}

Takahashi, Shinya ^{[14
]}

Ohdan, Hideki ^{[7
]}

机构：

[1] Hiroshima Mem Hosp, Dept Surg, 1-4-3 Honkawa Cho,Naka Ku, Hiroshima, Hiroshima 7300802, Japan

[2] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Perioperat & Crit Care Management, 1-2-3 Kasumi,Minami Ku, Hiroshima 7348551, Japan

[3] Hiroshima City North Med Ctr Asa Citizens Hosp, Dept Surg, Hiroshima, Japan

[4] JA Hiroshima Gen Hosp, Dept Surg, Hatsukaichi, Japan

[5] Natl Hosp Org, Higashihiroshima Med Ctr, Higashihiroshima, Japan

[6] JA Onomichi Gen Hosp, Dept Surg, Onomichi, Japan

[7] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg, Hiroshima, Japan

[8] Kure Med Ctr, Chugoku Canc Ctr, Dept Surg, Kure, Japan

[9] Chuden Hosp, Dept Surg, Hiroshima, Japan

[10] JR Hiroshima Hosp, Dept Surg, Hiroshima, Japan

[11] Miyoshi Cent Hosp, Dept Surg, Miyoshi, Japan

[12] Chugoku Rosai Hosp, Dept Surg, Kure, Japan

[13] JA Yoshida Gen Hosp, Dept Surg, Akitakata, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Surg, Hiroshima, Japan

来源：

GASTRIC CANCER | 2025年 / 28卷 / 01期

关键词：

Docetaxel; S1; Gastric cancer; Adjuvant chemotherapy; Tolerability; PERIOPERATIVE CHEMOTHERAPY; WEIGHT-LOSS; S-1; SURGERY;

D O I：

10.1007/s10120-024-01563-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundAdjuvant docetaxel plus S1 (DS) chemotherapy after gastrectomy with D2 lymph node dissection is the standard treatment for stage III gastric cancer in Japan; however, some patients are unable to receive adequate drug administration because of the deterioration of their conditions. This study aimed to investigate the correlation between tolerability for postoperative adjuvant DS chemotherapy and prognosis, and the factors affecting tolerability.MethodsThis retrospective study involved patients with stage III gastric cancer who underwent curative resection between 2018 and 2021 from a multicenter database. Patients with a cumulative dose of docetaxel and S1 greater than 120 and 8400 mg/m2, respectively, were considered tolerable. The prognostic impact and factors predicting tolerability were analyzed.ResultsOf the 103 patients, the tolerable group comprised of 63 (61%) patients and had a significantly better 3-year recurrence-free survival than the intolerable group (83% vs. 64%, P = 0.02). Among the preoperative factors, only performance status (PS, P = 0.04) was significantly correlated with tolerability in the univariate analysis. Among the postoperative factors, PS (P = 0.001) and perioperative weight loss rate (P = 0.02) were significantly correlated with tolerability in the univariate analysis. The multivariate analysis showed significant differences in the PS (odds ratio [OR]: 4.94, 95% confidence interval [CI] 1.79-14.98, P = 0.002) and weight loss rate (OR: 1.10, 95% CI 1.01-1.21, P = 0.03).ConclusionsTolerance to postoperative adjuvant DS chemotherapy has a significant prognostic impact. Postoperative PS and perioperative weight loss rates were independent predictors of tolerability.

引用

页码：102 / 111

页数：10

共 17 条

[1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[2] Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer [J].

Aoyama, Toru ;

Sato, Tsutomu ;

Maezawa, Yukio ;

Kano, Kazuki ;

Hayashi, Tsutomu ;

Yamada, Takanobu ;

Yukawa, Norio ;

Oshima, Takashi ;

Rino, Yasushi ;

Masuda, Munetaka ;

Ogata, Takashi ;

Cho, Haruhiko ;

Yoshikawa, Takaki .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) :476-483

[3] Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer [J].

Aoyama, Toru ;

Yoshikawa, Takaki ;

Shirai, Junya ;

Hayashi, Tsutomu ;

Yamada, Takanobu ;

Tsuchida, Kazuhito ;

Hasegawa, Shinichi ;

Cho, Haruhiko ;

Yukawa, Norio ;

Oshima, Takashi ;

Rino, Yasushi ;

Masuda, Munetaka ;

Tsuburaya, Akira .

ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) :2000-2006

[4] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

[5]

gco.iarc.who.int, Cancer Today

[6] Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis [J].

Iizuka, Akimitsu ;

Kanda, Mitsuro ;

Ito, Seiji ;

Mochizuki, Yoshinari ;

Teramoto, Hitoshi ;

Ishigure, Kiyoshi ;

Murai, Toshifumi ;

Asada, Takahiro ;

Ishiyama, Akiharu ;

Matsushita, Hidenobu ;

Tanaka, Chie ;

Kobayashi, Daisuke ;

Fujiwara, Michitaka ;

Murotani, Kenta ;

Kodera, Yasuhiro .

WORLD JOURNAL OF SURGERY, 2019, 43 (08) :2016-2024

[7]

James DB., 2017, TNM CLASSIFICATION M, V8

[8] Japanese gastric cancer treatment guidelines 2018 (5th edition) [J].

Japanese Gastric Cancer Association .

GASTRIC CANCER, 2021, 24 (01) :1-21

[9] Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07 [J].

Kakeji, Yoshihiro ;

Yoshida, Kazuhiro ;

Kodera, Yasuhiro ;

Kochi, Mitsugu ;

Sano, Takeshi ;

Ichikawa, Wataru ;

Lee, Sang-Woong ;

Shibahara, Kazushige ;

Shikano, Toshio ;

Kataoka, Masato ;

Ishiguro, Atsushi ;

Ojima, Hitoshi ;

Sakai, Yoshinori ;

Musha, Nobuyuki ;

Takase, Tsunenobu ;

Kimura, Taisei ;

Takeuchi, Masahiro ;

Fujii, Masashi .

GASTRIC CANCER, 2022, 25 (01) :188-196

[10] Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study [J].

Kodera, Yasuhiro ;

Yoshida, Kazuhiro ;

Kochi, Mitsugu ;

Sano, Takeshi ;

Ichikawa, Wataru ;

Kakeji, Yoshihiro ;

Sunakawa, Yu ;

Takeuchi, Masahiro ;

Fujii, Masashi .

GASTRIC CANCER, 2023, 26 (06) :1063-1068

← 1 2 →